European Union - English - EMA (European Medicines Agency)

pierre fabre medicament - busulfan - hematopoietic stem cell transplantation - antineoplastic agents - busilvex followed by cyclophosphamide (bucy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (hpct) in adult patients when the combination is considered the best available option.busilvex following fludarabine (fb) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (hpct) in adult patients who are candidates for a reduced-intensity conditioning (ric) regimen.busilvex followed by cyclophosphamide (bucy4) or melphalan (bumel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - busulfan - hematopoietic stem cell transplantation - alkyl sulfonates - busulfan fresenius kabi followed by cyclophosphamide (bucy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (hpct) in adult patients when the combination is considered the best available option.busulfan fresenius kabi followed by cyclophosphamide (bucy4) or melphalan (bumel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

European Union - English - EMA (European Medicines Agency)

intervet international bv - clostridium-perfringens-type-a alpha toxoid - immunologicals for aves - chicken - for the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.to reduce mortality and the incidence and severity of lesions caused by clostridium-perfringens-type-a-induced necrotic enteritis. efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.the onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.the duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.

European Union - English - EMA (European Medicines Agency)

intervet international bv - clostridium perfringens type c / escherichia coli f4ab / e. coli f4ac / e. coli f5 / e. coli f6 / e. coli lt - immunologicals - pigs - for the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those escherichia coli strains which express the adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) or f6 (987p) and caused by clostridium perfringens type c.,

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - live attenuated aujeszky's disease virus - immunologicals - pigs - active immunisation of pigs from the age of 10 weeks to prevent the mortality and clinical signs of aujeszky's disease and to reduce the excretion of aujeszky's disease field virus. passive immunisation of the progeny of vaccinated gilts and sows to reduce mortality and clinical signs of aujeszky's disease and to reduce the excretion of aujeszky's disease field virus.

European Union - English - EMA (European Medicines Agency)

adienne s.r.l. s.u. - thiotepa - hematopoietic stem cell transplantation - antineoplastic agents - in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.". it is proposed that tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastic agents - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - prohexadione-calcium - water dispersible granule - prohexadione-calcium plant growth regulator active 100.0 g/kg - plant regulator

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - prohexadione-calcium - water dispersible granule - prohexadione-calcium plant growth regulator active 100.0 g/kg - plant regulator

European Union - English - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - immunologicals for suidae - pigs - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.